Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on February 6, 2024, announcing its financial results for the fourth quarter and full year ended December 31, 2023. The report primarily serves to include the press release detailing these financial outcomes, which offers insights into the company's operational performance and financial condition. Investors should refer to the press release (Exhibit 99.1) for specific figures and management's commentary on the results. The company highlighted that it presents financial information on both a GAAP and a non-GAAP basis. Gilead emphasizes that non-GAAP measures are provided as a supplementary view, believed to be useful for investors, and are used internally for operational and financial planning. A reconciliation between GAAP and non-GAAP figures is available within the press release, which is crucial for a comprehensive understanding of the reported financial health and operational efficiency.
Key Highlights
- 1Gilead Sciences announced its Q4 and full-year 2023 financial results via an 8-K filing on February 6, 2024.
- 2The 8-K filing includes a press release (Exhibit 99.1) containing the detailed financial results.
- 3The company reports financial information using both U.S. Generally Accepted Accounting Principles (GAAP) and non-GAAP measures.
- 4Management believes non-GAAP financial information provides useful insights for investors and is used for internal operational and financial planning.
- 5A reconciliation between GAAP and non-GAAP financial measures is provided in the press release.
- 6The information furnished in this 8-K is not deemed 'filed' for certain purposes under the Securities Exchange Act of 1934, limiting liability under Section 18.